Take a look at the key takeaways from the recent CDDF Webinar on Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception which took place on 15 June 2023:
1️⃣ Advancements in preclinical biomarker identification and genetic profiling are key components for the future of cancer prevention clinical trials.
2️⃣ Cancer prevention clinical trials are high risk and funding agencies play a critical role to mitigating the risk for industry stakeholders to promote their engagement.
3️⃣ The U.S. National Cancer Institute (NCI) has implemented multiple programs to advance cancer prevention and interception agent development that are open to domestic and international sites, including academic, government and industry partners.
4️⃣ Window of opportunity studies can serve as a step up to the lengthy final studies that will be required for evidence generation in preventive cancer treatment.
This topic will be discussed and explored further at the 2023 AAADV-ASCO-CDDF Workshop on Global Cancer Drug Development on 13-15 September 2023. Stay tuned for more updates on www.aaadv.org